BOSTON, Oct. 19 /PRNewswire-FirstCall/ -- Experts from PAREXEL International Corporation , a leading global biopharmaceutical services provider, will address important industry issues at the Drug Information Association (DIA) 3rd Annual Clinical Forum, being held from October 19 - 21, 2009 in Nice, France. A number of PAREXEL’s thought leaders will present on topics ranging from pharmacovigilance reporting to centralized monitoring for late phase trials. Presentations from PAREXEL and its subsidiary, Perceptive Informatics, a leading eClinical solutions provider, will also discuss best practices for the integration of technology in post-marketing studies as well as data checks in Electronic Patient-Reported Outcomes (ePRO) based studies.
Attendees at the meeting will be able to learn more about capabilities related to these topics by visiting the PAREXEL Booth #16 or Perceptive Informatics Booth #13 in the exhibit hall. The DIA Annual Clinical Forum program features the following sessions:
Monday, October 19
Wednesday, October 21
For more information about PAREXEL visit www.PAREXEL.com or Booth #16, and for more information about Perceptive Informatics visit www.perceptive.com or Booth #13. Information about the meeting can be found at www.diahome.org.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 70 locations throughout 52 countries around the world, and has approximately 9,300 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone acquisition; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Annual Report on Form 10-K for the year ended June 30, 2009 as filed with the SEC on August 28, 2009, which “Risk Factors” discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company’s estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.
SOURCE PAREXEL International Corporation
CONTACT: Jennifer Baird, Senior Director of Public Relations, of PAREXEL
International, +1-781-434-4409, Jennifer.Baird@PAREXEL.com, or Gene
Carozza/Kim Baker of PAN Communications, +1-978-474-1900,
PAREXEL@pancomm.com
Web site: http://www.parexel.com/
